Radical Hypofractionated Radiotherapy for Localized Prostate Cancer
ConditionLocalized Prostate Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age18+
SponsorChanghai Hospital
About this trial
The aim of this trial is to study the safety outcomes of hypofractionated radiotherapy in treating patients with localized prostate cancer.
Hypofractionated radiotherapy delivers higher doses of radiotherapy in a shorter time period, may enabling the killing of more tumor cells with fewer side effects.
Accumulating evidence has proven the safety and feasibility of hypofractionated radiotherapy for localized prostate cancer.But for localized prostate cancer,the optimal dose per fraction of hypofractionated radiotherapy is still on its way.
Eligibility criteria
Qualifiers
Age: ≥18 years old;
European Cooperative Oncology Group score(ECOG):≤ 2;
Patients with pathologically diagnosed prostate cancer;
Clinical stage was cTanyN0M0 any Gleason / ISUP group;
Disqualifiers
Patients who have received any other early treatment for prostate cancer, including radiotherapy, chemotherapy, focal therapy, etc;
a previous history of pelvic and abdominal radiotherapy;
Prior hormonal therapy (castration or antiandrogen);
Patients with other malignancies and acute or chronic infections such as human immunodeficiency virus (HIV) (+), hepatitis C virus (HCV) (+) and/or positive syphilis;
Trial design
Treatments tested in this trial
- Hypofractionated radiation therapy
Treatment groups
20 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov